Log In
BCIQ
Print this Print this
 

VCE-003

  Manage Alerts
Collapse Summary General Information
Company VivaCell Biotechnology Espana S.L.
DescriptionNon-psychotropic cannabinoids derived from cannabigerol
Molecular Target Cannabinoid CB2 receptor (CNR2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS)
Regulatory Designation
PartnerAphios Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/17/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today